株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

組織診断の世界市場:製品別 (抗体、キット、スライド染色装置、組織処理装置)・技術別 (ISH、IHC、特殊染色)・疾患別 (乳がん、非小細胞肺がん (NSCLC)、リンパ腫)・エンドユーザー別の将来予測 (2025年まで)

Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User - Global Forecast to 2025

発行 MarketsandMarkets 商品コード 937810
出版日 ページ情報 英文 175 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
組織診断の世界市場:製品別 (抗体、キット、スライド染色装置、組織処理装置)・技術別 (ISH、IHC、特殊染色)・疾患別 (乳がん、非小細胞肺がん (NSCLC)、リンパ腫)・エンドユーザー別の将来予測 (2025年まで) Tissue Diagnostics Market by Product (Antibodies, Kits, Slide Staining System, Tissue Processing System), Technology (ISH, IHC, Special Staining), Disease (Breast Cancer, NSCLC, Lymphoma), End User - Global Forecast to 2025
出版日: 2020年05月14日 ページ情報: 英文 175 Pages
概要

世界の組織診断の市場規模は、2020年の34億米ドルから、2025年には47億米ドルへと、6.5%のCAGRで拡大する見通しです。市場成長の主な要因として、がんの発症率の上昇や、がん診断インフラの整備、がん検診の推奨、医療費償還の受けやすさ、医療費支出の増大などが挙げられます。製品別では消耗品向け支出額が、技術別では免疫組織化学関連が、地域別ではアジア太平洋地域が、今後大きく拡大する見込みです。

当レポートでは、世界の組織診断の市場について分析し、市場の基本構造や最新情勢、主な市場促進・阻害要因、市場動向の見通し (今後6年間分)、製品別・技術別・疾患別・エンドユーザー別・地域別の詳細動向、市場競争の状態、主要企業のプロファイルなどを調査しております。

937810_4.3 TISSUE DIAGNOSTIC MARKET_GEOGRAPHIC SNAPSHOT_FIGURE 13

第1章 イントロダクション

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概略

  • イントロダクション
  • 市場のダイナミクス
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
    • 課題
    • 市場動向

第6章 組織診断市場:製品別

  • イントロダクション
  • 消耗品
    • 抗体
    • キット
    • 試薬
    • プローブ
  • 診断装置
    • スライド染色装置
    • スキャナー
    • 組織処理装置
    • その他の装置

第7章 組織診断市場:技術別

  • イントロダクション
  • 免疫組織化学 (IHC)
  • in situ ハイブリダイゼーション (ISH)
  • デジタル病理学/ワークフロー管理
  • 特殊染色

第8章 組織診断市場:疾患別

  • イントロダクション
  • 乳がん
  • 胃がん
  • リンパ腫
  • 前立腺がん
  • 非小細胞肺がん (NSCLC)
  • その他の疾患

第9章 組織診断市場:エンドユーザー別

  • イントロダクション
  • 病院
  • 検査室
  • 製薬企業
  • CRO (医薬品開発業務受託機関)
  • その他のエンドユーザー

第10章 組織診断市場:組織別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州諸国
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋諸国
  • 他の国々 (RoW)
    • ラテンアメリカ
    • 中東・アフリカ

第11章 競争環境

  • 概要
  • 市場シェア分析
  • 競争シナリオ (2017~2020年)
    • 製品の上市
    • 製品の承認
    • 事業提携・協力
    • 企業買収
  • 企業戦略の方向性:マッピング
    • ベンダー選定基準
    • 先駆的企業
    • 活動的企業
    • 新規企業

第12章 企業プロファイル

  • ROCHE
  • DANAHER
  • THERMO FISHER SCIENTIFIC
  • ABBOTT
  • AGILENT TECHNOLOGIES
  • MERCK KGAA
  • サクラファインテックジャパン
  • ABCAM
  • BECTON, DICKINSON AND COMPANY (BD)
  • BIO SB
  • BIOGENEX
  • CELL SIGNALING TECHNOLOGY
  • HISTO-LINE LABORATORIES
  • SLEE MEDICAL GMBH
  • AMOS SCIENTIFIC PTY LTD
  • JINHUA YIDI MEDICAL APPLIANCE CO.LTD
  • MEDITE GMBH
  • CELLPATH LTD
  • HOLOGIC, INC.
  • DIPATH S.P.A.

第13章 付録

図表

LIST OF TABLES

  • TABLE 1 NUMBER OF PATHOLOGIST PER 100,000 POPULATION, BY COUNTRY, 2018 43
  • TABLE 2 TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 46
  • TABLE 3 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018-2025 (USD MILLION) 46
  • TABLE 4 TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY REGION, 2018-2025 (USD MILLION) 47
  • TABLE 5 TISSUE DIAGNOSTICS MARKET FOR ANTIBODIES, BY REGION, 2018-2025 (USD MILLION) 48
  • TABLE 6 TISSUE DIAGNOSTICS MARKET FOR KITS, BY REGION, 2018-2025 (USD MILLION) 48
  • TABLE 7 TISSUE DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2018-2025 (USD MILLION) 49
  • TABLE 8 TISSUE DIAGNOSTICS MARKET FOR PROBES, BY REGION, 2018-2025 (USD MILLION) 50
  • TABLE 9 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018-2025 (USD MILLION) 50
  • TABLE 10 TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2018-2025 (USD MILLION) 51
  • TABLE 11 TISSUE DIAGNOSTICS MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2018-2025 (USD MILLION) 52
  • TABLE 12 TISSUE DIAGNOSTICS MARKET FOR SCANNERS, BY REGION, 2018-2025 (USD MILLION) 52
  • TABLE 13 TISSUE DIAGNOSTICS MARKET FOR TISSUE-PROCESSING SYSTEMS, BY REGION, 2018-2025 (USD MILLION) 53
  • TABLE 14 TISSUE DIAGNOSTICS MARKET FOR OTHER INSTRUMENTS, BY REGION, 2018-2025 (USD MILLION) 54
  • TABLE 15 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 56
  • TABLE 16 TISSUE DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2025 (USD MILLION) 57
  • TABLE 17 TISSUE DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2018-2025 (USD MILLION) 59
  • TABLE 18 TISSUE DIAGNOSTICS MARKET FOR DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT, BY REGION, 2018-2025 (USD MILLION) 60
  • TABLE 19 TISSUE DIAGNOSTICS MARKET FOR SPECIAL STAINING, BY REGION, 2018-2025 (USD MILLION) 60
  • TABLE 20 GLOBAL CANCER INCIDENCE, 2018 VS.2025 62
  • TABLE 21 TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018-2025 (USD MILLION) 63
  • TABLE 22 BREAST CANCER INCIDENCE, BY REGION, 2018 VS. 2025 64
  • TABLE 23 TISSUE DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2018-2025 (USD MILLION) 65
  • TABLE 24 STOMACH CANCER INCIDENCE, BY REGION, 2018 VS. 2025 65
  • TABLE 25 TISSUE DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY REGION, 2018-2025 (USD MILLION) 66
  • TABLE 26 HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 67
  • TABLE 27 NON-HODGKIN LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025 67
  • TABLE 28 TISSUE DIAGNOSTICS MARKET FOR LYMPHOMA, BY REGION, 2018-2025 (USD MILLION) 68
  • TABLE 29 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025 68
  • TABLE 30 TISSUE DIAGNOSTICS MARKET FOR PROSTATE CANCER, BY REGION, 2018-2025 (USD MILLION) 69
  • TABLE 31 LUNG CANCER INCIDENCE, BY REGION, 2018 VS. 2025 70
  • TABLE 32 TISSUE DIAGNOSTICS MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2025 (USD MILLION) 71
  • TABLE 33 TISSUE DIAGNOSTICS MARKET FOR OTHER DISEASES, BY REGION, 2018-2025 (USD MILLION) 72
  • TABLE 34 TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 74
  • TABLE 35 TISSUE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018-2025 (USD MILLION) 75
  • TABLE 36 TISSUE DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES, BY REGION, 2018-2025 (USD MILLION) 75
  • TABLE 37 TISSUE DIAGNOSTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2018-2025 (USD MILLION) 76
  • TABLE 38 TISSUE DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2025 (USD MILLION) 77
  • TABLE 39 TISSUE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018-2025 (USD MILLION) 77
  • TABLE 40 TISSUE DIAGNOSTICS MARKET, BY REGION, 2018-2025 (USD MILLION) 79
  • TABLE 41 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION) 81
  • TABLE 42 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 81
  • TABLE 43 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018-2025 (USD MILLION) 81
  • TABLE 44 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018-2025 (USD MILLION) 82
  • TABLE 45 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018-2025 (USD MILLION) 82
  • TABLE 46 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 83
  • TABLE 47 NORTH AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 83
  • TABLE 48 US CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 84
  • TABLE 49 US: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 85
  • TABLE 50 US: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 85
  • TABLE 51 US: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 85
  • TABLE 52 CANADA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 86
  • TABLE 53 CANADA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 87
  • TABLE 54 CANADA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 87
  • TABLE 55 CANADA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 87
  • TABLE 56 EUROPE: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION) 88
  • TABLE 57 EUROPE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 89
  • TABLE 58 EUROPE: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018-2025 (USD MILLION) 89
  • TABLE 59 EUROPE: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018-2025 (USD MILLION) 89
  • TABLE 60 EUROPE: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018-2025 (USD MILLION) 90
  • TABLE 61 EUROPE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 90
  • TABLE 62 EUROPE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 90
  • TABLE 63 GERMANY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 91
  • TABLE 64 GERMANY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 92
  • TABLE 65 GERMANY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 92
  • TABLE 66 GERMANY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 92
  • TABLE 67 UK: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 93
  • TABLE 68 UK: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 94
  • TABLE 69 UK: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 94
  • TABLE 70 FRANCE CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 95
  • TABLE 71 FRANCE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 95
  • TABLE 72 FRANCE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 96
  • TABLE 73 FRANCE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 96
  • TABLE 74 ITALY CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 96
  • TABLE 75 ITALY: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 97
  • TABLE 76 ITALY: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 97
  • TABLE 77 ITALY: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 98
  • TABLE 78 SPAIN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 98
  • TABLE 79 SPAIN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 99
  • TABLE 80 SPAIN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 99
  • TABLE 81 SPAIN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 99
  • TABLE 82 KEY REST OF EUROPEAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025 100
  • TABLE 83 KEY REST OF EUROPEAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025 100
  • TABLE 84 KEY REST OF EUROPEAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025 100
  • TABLE 85 ROE: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 101
  • TABLE 86 ROE: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 101
  • TABLE 87 ROE: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 102
  • TABLE 88 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY COUNTRY, 2018-2025 (USD MILLION) 104
  • TABLE 89 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 104
  • TABLE 90 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018-2025 (USD MILLION) 104
  • TABLE 91 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018-2025 (USD MILLION) 105
  • TABLE 92 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018-2025 (USD MILLION) 105
  • TABLE 93 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 105
  • TABLE 94 ASIA PACIFIC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 106
  • TABLE 95 CHINA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 106
  • TABLE 96 CHINA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 107
  • TABLE 97 CHINA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 107
  • TABLE 98 CHINA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 108
  • TABLE 99 JAPAN CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 108
  • TABLE 100 JAPAN: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 109
  • TABLE 101 JAPAN: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 110
  • TABLE 102 JAPAN: TISSUE DIAGNOSTICS MARKET, BY END USER, 2017-2025 (USD MILLION) 110
  • TABLE 103 INDIA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 111
  • TABLE 104 INDIA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 112
  • TABLE 105 INDIA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 112
  • TABLE 106 INDIA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 112
  • TABLE 107 INCIDENCE OF CANCER IN ROPAC 113
  • TABLE 108 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 114
  • TABLE 109 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 114
  • TABLE 110 ROAPAC: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 114
  • TABLE 111 ROW: TISSUE DIAGNOSTICS MARKET, BY REGION, 2018-2025 (USD MILLION) 115
  • TABLE 112 ROW: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 115
  • TABLE 113 ROW: TISSUE DIAGNOSTICS MARKET FOR CONSUMABLES, BY TYPE, 2018-2025 (USD MILLION) 116
  • TABLE 114 ROW: TISSUE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY TYPE, 2018-2025 (USD MILLION) 116
  • TABLE 115 ROW: TISSUE DIAGNOSTICS MARKET, BY DISEASE, 2018-2025 (USD MILLION) 117
  • TABLE 116 ROW: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 117
  • TABLE 117 ROW: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 117
  • TABLE 118 KEY LATIN AMERICAN COUNTRIES LUNG CANCER INCIDENCE, 2018 VS. 2025 118
  • TABLE 119 KEY LATIN AMERICAN COUNTRIES LIVER CANCER INCIDENCE, 2018 VS. 2025 118
  • TABLE 120 KEY LATIN AMERICAN COUNTRIES BREAST CANCER INCIDENCE, 2018 VS. 2025 119
  • TABLE 121 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 119
  • TABLE 122 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 120
  • TABLE 123 LATIN AMERICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 120
  • TABLE 124 AFRICA CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025 121
  • TABLE 125 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY PRODUCT, 2018-2025 (USD MILLION) 121
  • TABLE 126 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2018-2025 (USD MILLION) 122
  • TABLE 127 MIDDLE EAST & AFRICA: TISSUE DIAGNOSTICS MARKET, BY END USER, 2018-2025 (USD MILLION) 122

LIST OF FIGURES

  • FIGURE 1 RESEARCH DESIGN 22
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 24
  • FIGURE 3 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 25
  • FIGURE 4 MARKET SIZE ESTIMATION FROM THE PARENT MARKET 25
  • FIGURE 5 DATA TRIANGULATION METHODOLOGY 26
  • FIGURE 6 TISSUE DIAGNOSTIC MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION) 28
  • FIGURE 7 TISSUE DIAGNOSTIC MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD MILLION) 29
  • FIGURE 8 TISSUE DIAGNOSTIC MARKET, BY DISEASE, 2020 VS. 2025 (USD MILLION) 29
  • FIGURE 9 TISSUE DIAGNOSTIC MARKET, BY END USER, 2020 VS. 2025 (USD MILLION) 30
  • FIGURE 10 GEOGRAPHIC SNAPSHOT OF THE GLOBAL TISSUE DIAGNOSTIC MARKET 31
  • FIGURE 11 RISING INCIDENCE OF CANCER TO DRIVE THE GROWTH OF THE TISSUE DIAGNOSTICS MARKET DURING THE FORECAST PERIOD 32
  • FIGURE 12 GASTRIC CANCER SEGMENT DOMINATED THE APAC MARKET IN 2019 33
  • FIGURE 13 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 34
  • FIGURE 14 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, CHALLENGES, AND TRENDS 36
  • FIGURE 15 CURRENT HEALTH EXPENDITURE PER CAPITA 37
  • FIGURE 16 CURRENT HEALTH EXPENDITURE (% OF GDP) 38
  • FIGURE 17 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012-2016 40
  • FIGURE 18 NUMBER OF ARTICLES RELATED TO TISSUE DIAGNOSTICS PUBLISHED ON PUBMED (2010-2019) 42
  • FIGURE 19 ARTICLES PUBLISHED ON CANCER TISSUE DIAGNOSTICS, 2010-2019 63
  • FIGURE 20 ARTICLES PUBLISHED ON BREAST CANCER TISSUE DIAGNOSTICS, 2010-2019 64
  • FIGURE 21 ARTICLES PUBLISHED ON GASTRIC CANCER TISSUE DIAGNOSTICS, 2010-2019 66
  • FIGURE 22 ARTICLES PUBLISHED ON LYMPHOMA TISSUE DIAGNOSTICS, 2010-2018 67
  • FIGURE 23 ARTICLES PUBLISHED ON PROSTATE CANCER TISSUE DIAGNOSTICS, 2010-2018 69
  • FIGURE 24 ARTICLES PUBLISHED ON NON-SMALL CELL LUNG CANCER TISSUE DIAGNOSTICS, 2010-2019 70
  • FIGURE 25 TISSUE DIAGNOSTICS MARKET IN NORTH AMERICA: SNAPSHOT 80
  • FIGURE 26 TISSUE DIAGNOSTICS MARKET IN ASIA PACIFIC: SNAPSHOT 103
  • FIGURE 27 PRODUCT LAUNCHES─THE MOST ADOPTED GROWTH STRATEGY FROM 2017 TO 2020 123
  • FIGURE 28 SHARES OF TOP COMPANIES IN THE GLOBAL TISSUE DIAGNOSTIC MARKET (2019) 124
  • FIGURE 29 TISSUE DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING 128
  • FIGURE 30 ROCHE: COMPANY SNAPSHOT (2019) 129
  • FIGURE 31 DANAHER: COMPANY SNAPSHOT (2019) 133
  • FIGURE 32 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019) 136
  • FIGURE 33 ABBOTT: COMPANY SNAPSHOT (2019) 139
  • FIGURE 34 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019) 141  
  • FIGURE 35 MERCK: COMPANY SNAPSHOT (2019) 143
  • FIGURE 36 ABCAM: COMPANY SNAPSHOT (2019) 147
  • FIGURE 37 BD: COMPANY SNAPSHOT (2019) 149
  • FIGURE 38 HOLOGIC, INC: COMPANY SNAPSHOT (2019) 162
目次
Product Code: MD 2349

"The global tissue diagnostic market size is projected to register a CAGR of 6.5% during the forecast period."

The global tissue diagnostics market is expected to reach USD 4.7 billion by 2025 from USD 3.4 billion in 2020, at a CAGR of 6.5%. The growth in this market is driven by rising incidence of cancer, developing infrastructure for cancer diagnosis, the recommendation of cancer screening, availability of reimbursements, and increasing healthcare expenditure.

"The consumables segment is anticipated to grow at the fastest growth rate during the forecast period"

Based on product type, the tissue diagnostics market is segmented into instruments and consumables. The consumables segment is expected to grow at the highest growth rate during the forecast period. The large market share of this segment is driven mainly by their requirement in large numbers, cost-effectiveness, and ease of use. The increasing number of reagent rental agreements is also one of the major factors to drive the growth of the consumables market globally.

"The immunohistochemistry segment is estimated to grow at a rapid rate during the analysis period"

Based on the technology type, the tissue diagnostic market is segmented into immunohistochemistry, in situ hybridization, digital pathology and workflow, and special staining. The immunohistochemistry segment is estimated to register the highest CAGR during the forecast period. This can primarily be attributed to is increasing prevalence of chronic diseases across the globe, where this technology is mostly used in tissue diagnostics.

"Asia Pacific is estimated to register the highest CAGR during the study period"

Geographically, the tissue diagnostic market is dominated by North America and followed by Europe in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. Economic growth in the countries of this region, large population base, rising prevalence of chronic diseases, rising standard of living, growing demand for quality medical care, increasing healthcare spending, increasing government initiatives, and rising awareness regarding the use of tissue diagnostic tests, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:

  • By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
  • By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
  • By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

The key players in the tissue diagnostic market include Roche (Switzerland), Danaher (US), Thermo Fisher Scientific (US), Abbott (US), Agilent Technologies (US), ABCAM (UK), Merck KGAA (Germany), BD (US), Hologic (US), Bio Rad (US), Biomeriux (France), Sakura Fientek Japan (Japan), BioSB (US), Biogenex (US), Cell Signaling Technology (US), Histoline Laboratories (Italy), Slee Medical GMBH (Germany), Amos Scientific PTY Ltd (Australia), Jinhua Yidi Medical Appliance Co.Ltd (China), Medite GMBH (Germany), Cellpath Ltd(UK), Dipath S.P.A. (Italy).

Research Coverage:

The report analyzes the tissue diagnostic market by product, technology, disease, end user, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any 1, or a combination of the below mentioned 5 strategies to increase their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the products of the top players in the tissue diagnostic market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the tissue diagnostic market
  • Market Development: Detailed information about emerging markets.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostic market

TABLE OF CONTENTS

1 INTRODUCTION 19

  • 1.1 OBJECTIVES OF THE STUDY 19
  • 1.2 MARKET DEFINITION 19
  • 1.3 MARKET SCOPE 20
    • 1.3.1 MARKETS COVERED 20
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY 21
  • 1.4 CURRENCY 21
  • 1.5 LIMITATIONS 21
  • 1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22

  • 2.1 RESEARCH DATA 22
    • 2.1.1 SECONDARY DATA 23
      • 2.1.1.1 Key data from secondary sources 23
    • 2.1.2 PRIMARY DATA 24
  • 2.2 MARKET SIZE ESTIMATION 24
    • 2.2.1 BOTTOM-UP APPROACH 24
    • 2.2.2 GROWTH FORECAST 25
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
  • 2.4 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 32

  • 4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE TISSUE DIAGNOSTIC MARKET 32
  • 4.2 ASIA PACIFIC MARKET: BY DISEASE 33
  • 4.3 TISSUE DIAGNOSTIC MARKET: GEOGRAPHIC SNAPSHOT 34

5 MARKET OVERVIEW 35

  • 5.1 INTRODUCTION 35
  • 5.2 MARKET DYNAMICS 36
    • 5.2.1 DRIVERS 36
      • 5.2.1.1 Increasing incidence of cancer 36
      • 5.2.1.2 Growing healthcare expenditure 37
      • 5.2.1.3 Developing infrastructure for cancer diagnosis 38
      • 5.2.1.4 Recommendations for cancer screening 39
      • 5.2.1.5 Availability of reimbursements 39
    • 5.2.2 RESTRAINTS 39
      • 5.2.2.1 High degree of consolidation 39
    • 5.2.3 OPPORTUNITIES 40
      • 5.2.3.1 Significant opportunities in BRICS countries 40
      • 5.2.3.2 Growing demand for personalized medicines 40
      • 5.2.3.3 Increasing number of clinical trials pertaining to cancer drugs 41
    • 5.2.4 CHALLENGES 42
      • 5.2.4.1 Stringent regulatory requirements 42
      • 5.2.4.2 Lack of infrastructure and low awareness in middle- and low- income countries 42
      • 5.2.4.3 Availability of refurbished products 43
      • 5.2.4.4 Lack of skilled professionals 43
      • 5.2.4.5 Product failures and recalls 43
    • 5.2.5 TRENDS 44
      • 5.2.5.1 Increasing number of reagent rental agreements 44

6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT 45

  • 6.1 INTRODUCTION 46
  • 6.2 CONSUMABLES 46
    • 6.2.1 ANTIBODIES 47
    • 6.2.2 KITS 48
    • 6.2.3 REAGENTS 49
    • 6.2.4 PROBES 49
  • 6.3 INSTRUMENTS 50
    • 6.3.1 SLIDE-STAINING SYSTEMS 51
    • 6.3.2 SCANNERS 52
    • 6.3.3 TISSUE-PROCESSING SYSTEMS 53
    • 6.3.4 OTHER INSTRUMENTS 53

7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY 55

  • 7.1 INTRODUCTION 56
  • 7.2 IMMUNOHISTOCHEMISTRY (IHC) 56
  • 7.3 IN SITU HYBRIDIZATION (ISH) 58
  • 7.4 DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT 59
  • 7.5 SPECIAL STAINING 60

8 TISSUE DIAGNOSTICS MARKET, BY DISEASE 61

  • 8.1 INTRODUCTION 62
  • 8.2 BREAST CANCER 63
  • 8.3 GASTRIC CANCER 65
  • 8.4 LYMPHOMA 66
  • 8.5 PROSTATE CANCER 68
  • 8.6 NON-SMALL CELL LUNG CANCER (NSCLC) 69
  • 8.7 OTHER DISEASES 71

9 TISSUE DIAGNOSTICS MARKET, BY END USER 73

  • 9.1 INTRODUCTION 74
  • 9.2 HOSPITALS 74
  • 9.3 RESEARCH LABORATORIES 75
  • 9.4 PHARMACEUTICAL COMPANIES 76
  • 9.5 CONTRACT RESEARCH ORGANIZATIONS 76
  • 9.6 OTHER END USERS 77

10 TISSUE DIAGNOSTICS MARKET, BY REGION 78

  • 10.1 INTRODUCTION 79
  • 10.2 NORTH AMERICA 79
    • 10.2.1 US 83
      • 10.2.1.1 US is expected to be dominant country-level market for tissue diagnostics 83
    • 10.2.2 CANADA 86
      • 10.2.2.1 High prevalence of cancer in Canada is expected to support market growth 86
  • 10.3 EUROPE 88
    • 10.3.1 GERMANY 91
      • 10.3.1.1 Availability of reimbursements for colorectal cancer screening 91
    • 10.3.2 UK 93
      • 10.3.2.1 Government initiatives to drive the growth in the UK 93
    • 10.3.3 FRANCE 94
      • 10.3.3.1 Increasing government funding for cancer diagnosis & prevention to support the market growth 94
    • 10.3.4 ITALY 96
      • 10.3.4.1 High incidence of cancer to support the market growth in Italy 96
    • 10.3.5 SPAIN 98
      • 10.3.5.1 High incidence of chronic diseases to drive the Spanish market 98
    • 10.3.6 REST OF EUROPE (ROE) 100
  • 10.4 ASIA PACIFIC 102
    • 10.4.1 CHINA 106
      • 10.4.1.1 Increasing healthcare expenditure 106
    • 10.4.2 JAPAN 108
      • 10.4.2.1 Advanced healthcare infrastructure to support market growth in Japan 108
    • 10.4.3 INDIA 110
      • 10.4.3.1 Expanding healthcare sector in the country to drive market growth 110
    • 10.4.4 REST OF ASIA PACIFIC (ROAPAC) 113
  • 10.5 REST OF THE WORLD (ROW) 115
    • 10.5.1 LATIN AMERICA 118
      • 10.5.1.1 Increasing number of cancer screening programs to support market growth 118
    • 10.5.2 MIDDLE EAST & AFRICA 120
      • 10.5.2.1 Increasing incidence of cancer in the Middle East & Africa to support market growth 120

11 COMPETITIVE LANDSCAPE 123

  • 11.1 OVERVIEW 123
  • 11.2 MARKET SHARE ANALYSIS, 2019 124
  • 11.3 COMPETITIVE SCENARIO 125
    • 11.3.1 PRODUCT LAUNCHES (2017-2020) 125
    • 11.3.2 PRODUCT APPROVALS (2017-2020) 125
    • 11.3.3 PARTNERSHIPS AND COLLABORATIONS (2017-2020) 126
    • 11.3.4 ACQUISITIONS (2017-2020) 126
  • 11.4 COMPETITIVE LEADERSHIP MAPPING (2018) 127
    • 11.4.1 VENDOR INCLUSION CRITERIA 127
    • 11.4.2 VISIONARY LEADERS 127
    • 11.4.3 DYNAMIC DIFFERENTIATORS 127
    • 11.4.4 EMERGING COMPANIES 127

12 COMPANY PROFILES 129

(Business overview, Products offered, Recent developments, MNM view)*

  • 12.1 ROCHE 129
  • 12.2 DANAHER 133
  • 12.3 THERMO FISHER SCIENTIFIC 136
  • 12.4 ABBOTT 139
  • 12.5 AGILENT TECHNOLOGIES 141
  • 12.6 MERCK KGAA 143
  • 12.7 SAKURA FINETEK JAPAN 145
  • 12.8 ABCAM 147
  • 12.9 BECTON, DICKINSON AND COMPANY (BD) 149
  • 12.10 BIO SB 151
  • 12.11 BIOGENEX 152
  • 12.12 CELL SIGNALING TECHNOLOGY 154
  • 12.13 HISTO-LINE LABORATORIES 155
  • 12.14 SLEE MEDICAL GMBH 157
  • 12.15 AMOS SCIENTIFIC PTY LTD 158
  • 12.16 JINHUA YIDI MEDICAL APPLIANCE CO.LTD 159
  • 12.17 MEDITE GMBH 160
  • 12.18 CELLPATH LTD 161
  • 12.19 HOLOGIC, INC. 162
  • 12.20 DIPATH S.P.A. 164

Business overview, Products offered, Recent developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX 166

  • 13.1 INDUSTRY INSIGHTS 166
  • 13.2 DISCUSSION GUIDE 167
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 170
  • 13.4 AVAILABLE CUSTOMIZATIONS 172
  • 13.5 RELATED REPORTS 173
  • 13.6 AUTHOR DETAILS 174